Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease
| Status: | Completed |
|---|---|
| Conditions: | Parkinsons Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 30 - Any |
| Updated: | 4/5/2019 |
| Start Date: | November 2006 |
| End Date: | July 2014 |
Assessing the Determinants of PD Progression - Long-term Dopamine Transporter Imaging in the PRECEPT Cohort
The purpose of this study is to investigate the utility of dopamine transporter imaging in
monitoring and predicting the progression of Parkinson disease. This study will be performed
in the PRECEPT cohort, an already existing cohort of 806 subjects recruited to participate in
the study called, A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to
Assess the Efficacy and Safety of CEP-1347 in Patients With Early Parkinson's Disease -
(PRECEPT), sponsored by Cephalon and Lundbeck and coordinated by the Parkinson Study Group.
The imaging data from this long-term PRECEPT follow-up study will allow us to evaluate the
long-term progression of DAT loss in PD, the long-term follow-up of SWEDD subjects, the
relationship between long-term clinical and imaging PD outcomes, and the relationship between
long-term imaging outcomes and genetic and biochemical biomarkers of PD progression.
monitoring and predicting the progression of Parkinson disease. This study will be performed
in the PRECEPT cohort, an already existing cohort of 806 subjects recruited to participate in
the study called, A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to
Assess the Efficacy and Safety of CEP-1347 in Patients With Early Parkinson's Disease -
(PRECEPT), sponsored by Cephalon and Lundbeck and coordinated by the Parkinson Study Group.
The imaging data from this long-term PRECEPT follow-up study will allow us to evaluate the
long-term progression of DAT loss in PD, the long-term follow-up of SWEDD subjects, the
relationship between long-term clinical and imaging PD outcomes, and the relationship between
long-term imaging outcomes and genetic and biochemical biomarkers of PD progression.
The 800 early PD subjects in this study have already been evaluated clinically and have
undergone longitudinal dopamine transporter (DAT) imaging with [123I] ß-CIT (baseline and 22
months). In Follow-up imaging will be performed at 24-month intervals (46 and 70 months
following PRECEPT baseline). All scanning procedures will be performed at the Institute for
Neurodegenerative Disorders (IND) using methods previously employed in the PRECEPT study.
Subjects willing to participate will travel to New Haven for their 46-month imaging visit. At
IND a study coordinator and a neurologist will evaluate all subjects. The coordinator and
neurologist will discuss the study procedures and evaluate the patient for eligibility.
Written informed consent for the study will be obtained prior to performing any study-related
procedures.
If eligible, participants will be injected with ß-CIT and 24 hours later an imaging procedure
will be used to obtain pictures of brain activity using single photon emission computed
tomography (SPECT). This 2-day procedure will be repeated at 70 months (following PRECEPT
baseline).
undergone longitudinal dopamine transporter (DAT) imaging with [123I] ß-CIT (baseline and 22
months). In Follow-up imaging will be performed at 24-month intervals (46 and 70 months
following PRECEPT baseline). All scanning procedures will be performed at the Institute for
Neurodegenerative Disorders (IND) using methods previously employed in the PRECEPT study.
Subjects willing to participate will travel to New Haven for their 46-month imaging visit. At
IND a study coordinator and a neurologist will evaluate all subjects. The coordinator and
neurologist will discuss the study procedures and evaluate the patient for eligibility.
Written informed consent for the study will be obtained prior to performing any study-related
procedures.
If eligible, participants will be injected with ß-CIT and 24 hours later an imaging procedure
will be used to obtain pictures of brain activity using single photon emission computed
tomography (SPECT). This 2-day procedure will be repeated at 70 months (following PRECEPT
baseline).
Inclusion Criteria:
- Subject was a participant in the PRECEPT clinical and imaging study
- Participant must be willing and able to comply with study procedures
- Participant must be willing and able to give informed consent.
Exclusion Criteria:
- The participant has a clinically significant clinical laboratory value and/or medical
or psychiatric illness
- The participant has dementia (MMSE≤24)
- Pregnancy
We found this trial at
1
site
Click here to add this to my saved trials
